8β, 11β, 12α-PGF2.sub.β -compounds

ABSTRACT

This invention is a group of 8-beta, 12-alpha-PG 2  (prostaglandin-type) analogs having variable chain length, or methyl or phenyl substitution in the hydroxy-substituted side-chain, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, and labor inducement at term.

CROSS REFERENCE TO RELATED APPLICATIONS

This is a division of application Ser. No. 374,405, filed June 28, 1973, which is a continuation-in-part of my copending application Ser. No. 289,317 filed Sept. 15, 1972 now abandoned.

The present invention relates to prostaglandin analogs, for which the essential material constituting a disclosure thereof is incorporated by reference here from Ser. No. 518,436, filed Oct. 29, 1974, now pending issuance as a U.S. Patent. 

I claim:
 1. An optically active compound of the formula ##EQU1## wherein R₄, R₅, and R₇ are hydrogen or methyl, being the same or different; with the proviso that at least one of R₄ and R₅ is methyl; andWherein R₁₃ is hydrogen, alkyl of one to 10 carbon atoms, inclusive, cycloalkyl of 3 to 10 carbon atoms, inclusive, aralkyl of 10 to 12 carbon atoms, inclusive, phenyl, or phenyl substituted with one, 2, or 3 chloro or alkyl of one to 4 carbon atoms, inclusive; including the lower alkanoates thereof, and the pharmacologically acceptable salts thereof when R₁₃ is hydrogen.
 2. A compound according to claim 1, wherein R₄ and R₅ are methyl.
 3. 16,16-Dimethyl-8β,11β,12α-PGF₂.sub.β, a compound according to claim
 2. 4. 16,16-Dimethyl-8β,11β,12α-PGF₂.sub.β, methyl ester a compound according to claim
 2. 5. An optically active compound of the formula ##EQU2## wherein R₁₃ is hydrogen, alkyl of one to 10 carbon atoms, inclusive, cycloalkyl of 3 to 10 carbon atoms, inclusive, aralkyl of 10 to 12 carbon atoms, inclusive, phenyl, or phenyl substituted with one, 2, or 3 chloro or alkyl of one to 4 carbon atoms, inclusive;Including the lower alkanoates thereof, and the pharmacologically acceptable salts thereof wherein R₁₃ is hydrogen; Wherein R₂₂ is alkyl of one to 4 carbon atoms, inclusive; including the lower alkanoates thereof, and the pharmacologically acceptable salts thereof wherein R₁₃ is hydrogen. 